The Relationship Between Myocardial Infarction and Estrogen Use: A Literature Review

被引:5
作者
Javed, Ayesha [1 ]
Ravi, Phanish C. [2 ]
Delvi, Sarah Bilal [3 ]
Hussain, Iqra Faraz [4 ]
Acosta, G. Arnaldo J. [5 ]
Iqbal, Warda [4 ]
Krishnamaneni, Vamsi [6 ]
Alasaadi, Saya [7 ]
Pradhan, Swetapadma [8 ]
Vashisht, Rishabh [9 ]
Modi, Shivani [10 ]
机构
[1] Hearts Int Hosp, Gynecol, Rawalpindi, Pakistan
[2] Sri Venkata Sai Med Coll, Med & Surg, Hyderabad, Telangana, India
[3] Vydehi Inst Med Sci & Res Ctr, Internal Med, Bangalore, India
[4] Karachi Med & Dent Coll, Gynecol, Karachi, Pakistan
[5] Alfredo Van Grieken Univ Hosp, Endocrinol, Coro, Venezuela
[6] Katuri Med Coll & Hosp, Internal Med, Guntur, India
[7] Univ Coll Dublin, Med, Dublin, Ireland
[8] European Univ, Med, Fac Med, Tbilisi, Georgia
[9] Non Resident Indian NRI Med Coll, Internal Med, Vijayawada, India
[10] Albert Einstein Healthcare Network, Internal Med, Philadelphia, PA 19141 USA
关键词
cvd; transdermal estrogen; estrone; estradiol; myocardial infarction; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; ORAL-CONTRACEPTIVES; HORMONE-THERAPY; PROGESTIN; OUTCOMES; EVENTS; RISK;
D O I
10.7759/cureus.46134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This thorough literature evaluation was prompted by significant research into the complex interactions between estrogen use and myocardial infarction (MI). Estrogen has fascinated researchers because of its possible cardioprotective benefits and its impact on cardiovascular health. In order to clarify the connection between estrogen use and the risk of MI, this review critically examines the body of prior evidence.This review focuses on estrogen and its pivotal role in cardiovascular health, concentrating on lipid metabolism, vasodilation, inflammation, and endothelial function. It examines contentious data about estrogen therapy's heart-protective effects, taking into account age, initiation timing, dosage, and dosage of administration. Genetic and epigenetic influences on MI risk among estrogen users highlight intricate, personalized estrogen effects.The conclusion summarizes the main findings and emphasizes the need for an all-encompassing strategy for initiating and managing estrogen medication. It is crucial to consider patient-specific traits and risk factors to successfully customize treatment regimens. This review sheds vital light on the potential directions for better cardiovascular treatment for postmenopausal women by shedding light on the complex link between estrogen use and myocardial infarction. The review also identifies research gaps and future objectives in this area, highlighting the demand for novel medicines and individualized strategies to improve cardiovascular outcomes.
引用
收藏
页数:7
相关论文
共 31 条
[1]   17β-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway [J].
Babiker, FA ;
De Windt, LJ ;
van Eickels, M ;
Thijssen, V ;
Bronsaer, RJP ;
Grohé, C ;
van Bilsen, M ;
Doevendans, PA .
CIRCULATION, 2004, 109 (02) :269-276
[2]   Lifetime Risks of Cardiovascular Disease [J].
Berry, Jarett D. ;
Dyer, Alan ;
Cai, Xuan ;
Garside, Daniel B. ;
Ning, Hongyan ;
Thomas, Avis ;
Greenland, Philip ;
Van Horn, Linda ;
Tracy, Russell P. ;
Lloyd-Jones, Donald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :321-329
[3]   A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury [J].
Bopassa, Jean Chrisostome ;
Eghbali, Mansoureh ;
Toro, Ligia ;
Stefani, Enrico .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2010, 298 (01) :H16-H23
[4]   Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events [J].
Brieger, D. ;
Fox, K. A. A. ;
FitzGerald, G. ;
Eagle, K. A. ;
Budaj, A. ;
Avezum, A. ;
Granger, C. B. ;
Costa, B. ;
Anderson, F. A., Jr. ;
Steg, Ph G. .
HEART, 2009, 95 (11) :888-894
[5]   Estrogen and progestin components of oral contraceptives: Relationship to vascular disease [J].
Carr, BR ;
Ory, H .
CONTRACEPTION, 1997, 55 (05) :267-272
[6]   The epidemiology of cardiovascular disease in postmenopausal women [J].
Crawford, SL ;
Johannes, CB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06) :1803-1806
[7]  
Delgado B.J., 2023, Estrogen
[8]   The 2022 hormone therapy position statement of The North American Menopause Society [J].
Faubion, Stephanie S. ;
Crandall, Carolyn J. ;
Davis, Lori ;
El Khoudary, Samar R. ;
Hodis, Howard N. ;
Lobo, Roger A. ;
Maki, Pauline M. ;
Manson, JoAnn E. ;
Pinkerton, JoAnn V. ;
Santoro, Nanette F. ;
Shifren, Jan L. ;
Shufelt, Chrisandra L. ;
Thurston, Rebecca C. ;
Wolfman, Wendy .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (07) :767-794
[9]   The epigenetics of estrogen Epigenetic regulation of hormone-induced memory enhancement [J].
Frick, Karyn M. ;
Zhao, Zaorui ;
Fan, Lu .
EPIGENETICS, 2011, 6 (06) :675-680
[10]   Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries [J].
Gaziano, Thomas A. ;
Bitton, Asaf ;
Anand, Shuchi ;
Abrahams-Gessel, Shafika ;
Murphy, Adrianna .
CURRENT PROBLEMS IN CARDIOLOGY, 2010, 35 (02) :72-115